| Gene symbol | TTR | Synonyms | ATTR, CTS, CTS1, HEL111, HsT2651, PALB, TBPA, TTN | Type of gene | protein-coding |
| Chromosome | 18 | Map location | 18q12.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | transthyretin | ||||
| GTO ID | GTC1661 |
| Trial ID | NCT02939820 |
| Disease | Familial Amyloid Neuropathy | Amyloidosis |
| Altered gene | TTR |
| Therapeutic/Target gene | Target gene |
| Therapy | siRNA |
| Treatment | ALN-TTR02|ONPATTRO|patisiran |
| Location approved | US, EU, UK, Japan, Canada, Switzerland, Brazil, China, Israel, Turkey, Australia |
| Recruitment status | No Longer Available |
| Title | Expanded Access Protocol of Patisiran for Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With Polyneuropathy |
| Year | 2016 |
| Country | United States |
| Company sponsor | Alnylam Pharmaceuticals |
| Other ID(s) | ALN-TTR02-007 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||
|
|||||||